Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05944783 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05944783 · ClinicalTrials.gov record · last posted 2025-02-12

Bioequivalence Studies of Dasatinib 100 Mg

Study acronym: BE-Dasatinib
StatusNot Yet Recruiting
PhasePhase 4
Started2025-09-01
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 12, 2025 (before its estimated December 20, 2025 completion). Its status may not reflect the trial's current state.
from the ClinicalTrials.gov record
A bioequivalence study of Dasatinib will be carried out in 46 healthy subjects, in fed condition, following the complete replicated design, randomized, comparative of 2 sequences, 2 study formulations, in a single dose of 100 mg of Dasatinib tablets / coated tablets, 4 periods. , with a washout time of 7 days between each dose

Amendment record 1 amendment on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended once since 2023-07-12. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

Trial Details
NCT Number NCT05944783
Lead Sponsor Centro de Atencion e Investigacion Medica
Conditions Myeloma Multiple
Enrollment 46 participants
Start Date 2025-09-01
Primary Completion 2025-12-20 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-12